Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

In this retrospective, single-center study, we aimed to validate the RR6 model, compare its performance with currently validated prognostic models, and explore the independent contribution of genetic factors. The study was conducted in accordance with European and Italian regulations, and was approved by the ethical committees of each institution. The study included 105 patients with World Health Organization-defined MF who were treated with Rux at CRIMM (Florence, Italy), fully annotated for clinical and genetic variables, the latter available in 103 of 105 (98%) patients.